

## ASX ANNOUNCEMENT

### Tacere shares released from escrow

**SYDNEY Australia, 23 October 2013:** Benitec Biopharma Limited (“the Company”) advises that 2,114,639 fully paid ordinary shares of the Company will be released from voluntary escrow on 30 October 2013.

The shares were issued as part of the consideration for the acquisition of Tacere Therapeutics Inc. (“Tacere”), and were subject to voluntary escrow for 12 months from the date of issue. These are post consolidation shares representing 52,865,970 pre-consolidation shares before the 25 to 1 consolidation in July this year (after rounding).

The company will also issue 955,002 fully paid ordinary shares on the same date to vendors of Tacere. These shares were agreed to be issued 12 months after completion of the acquisition of Tacere, subject to satisfaction of conditions subsequent each of which has been satisfied. These shares are post-consolidation shares representing 23,875,039 pre-consolidation shares. These shares are to be issued at the same deemed issue price as the other shares issued as consideration for the acquisition of Tacere (1.496 cents pre-consolidation, equal to 37.4 cents post consolidation). Further shareholder approval to issue these shares is not required. The original Tacere agreement has monthly caps of AUD \$180,000 on the value of all shares which may be sold by the Tacere vendors. An Appendix 3B will be lodged when the new shares are issued.

**For more information please contact:** Greg West | Company Secretary  
Phone: +61 (02) 9555 6986 | [gwest@benitec.com](mailto:gwest@benitec.com) | [www.benitec.com](http://www.benitec.com)

**About Benitec Biopharma Limited:** Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington’s disease. For more information on Benitec refer to the Company’s website at [www.benitec.com](http://www.benitec.com).